spectrum's core mission is to bring pharmaceutical products to patients for unmet medical needs. to this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (all) and one for multiple myeloma. there are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.
Company profile
Ticker
SPPI
Exchange
Website
CEO
Joseph W. Turgeon
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NEOTHERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
Spectrum Oncology Private Limited • Spectrum Pharmaceuticals International Holdings, LLC • Allos Therapeutics, Inc. • Spectrum Pharmaceuticals Cayman, L.P. • Spectrum Pharmaceuticals, B.V. • Spectrum Pharmaceuticals Canada, Inc. • Talon Therapeutics, Inc. ...
IRS number
930979187
SPPI stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
9 Nov 23
EFFECT
Notice of effectiveness
28 Sep 23
EFFECT
Notice of effectiveness
28 Sep 23
EFFECT
Notice of effectiveness
28 Sep 23
EFFECT
Notice of effectiveness
28 Sep 23
EFFECT
Notice of effectiveness
28 Sep 23
EFFECT
Notice of effectiveness
28 Sep 23
EFFECT
Notice of effectiveness
28 Sep 23
EFFECT
Notice of effectiveness
28 Sep 23
EFFECT
Notice of effectiveness
28 Sep 23
Transcripts
SPPI
Earnings call transcript
2022 Q4
22 Mar 23
SPPI
Earnings call transcript
2022 Q3
11 Nov 22
SPPI
Earnings call transcript
2022 Q2
11 Aug 22
SPPI
Earnings call transcript
2022 Q1
12 May 22
SPPI
Earnings call transcript
2021 Q4
18 Mar 22
SPPI
Earnings call transcript
2021 Q3
11 Nov 21
SPPI
Earnings call transcript
2021 Q2
12 Aug 21
SPPI
Earnings call transcript
2021 Q1
14 May 21
SPPI
Earnings call transcript
2020 Q4
31 Mar 21
SPPI
Earnings call transcript
2020 Q3
4 Nov 20
Latest ownership filings
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 52.37 mm | 52.37 mm | 52.37 mm | 52.37 mm | 52.37 mm | 52.37 mm |
Cash burn (monthly) | (no burn) | 2.19 mm | 1.67 mm | 5.64 mm | 7.15 mm | 7.34 mm |
Cash used (since last report) | n/a | 27.71 mm | 21.09 mm | 71.28 mm | 90.33 mm | 92.83 mm |
Cash remaining | n/a | 24.67 mm | 31.28 mm | -18.91 mm | -37.96 mm | -40.46 mm |
Runway (months of cash) | n/a | 11.3 | 18.7 | -3.4 | -5.3 | -5.5 |
Institutional ownership, Q2 2023
35.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 72 |
Opened positions | 18 |
Closed positions | 16 |
Increased positions | 13 |
Reduced positions | 17 |
13F shares | Current |
---|---|
Total value | 49.13 bn |
Total shares | 72.76 mm |
Total puts | 113.40 k |
Total calls | 482.00 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 20.00 mm | $19.20 bn |
Hanmi Pharmaceutical | 15.33 mm | $14.95 mm |
Vanguard | 8.58 mm | $8.24 bn |
Kennedy Capital Management | 4.88 mm | $4.69 bn |
BLK Blackrock | 3.48 mm | $3.34 bn |
Acadian Asset Management | 2.91 mm | $2.79 mm |
Ergoteles | 2.33 mm | $2.24 bn |
Geode Capital Management | 1.78 mm | $1.71 bn |
Renaissance Technologies | 1.42 mm | $1.36 mm |
New York Life Investment Management | 1.38 mm | $1.32 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Jul 23 | Riga Thomas J | Common Stock, $0.001 par value | Sale back to company | Dispose D | No | No | 0 | 1,317,694 | 0.00 | 0 |
31 Jul 23 | Riga Thomas J | Common Stock, $0.001 par value | Sale back to company | Dispose D | No | No | 0 | 204,471 | 0.00 | 0 |
31 Jul 23 | Riga Thomas J | Common Stock, $0.001 par value | Sale back to company | Dispose D | No | No | 0 | 317,474 | 0.00 | 0 |
31 Jul 23 | Riga Thomas J | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 1.29 | 1,078,500 | 1.39 mm | 0 |
31 Jul 23 | Riga Thomas J | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.63 | 2,567,440 | 1.62 mm | 0 |
31 Jul 23 | Riga Thomas J | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.38 | 3,112,000 | 1.18 mm | 0 |
31 Jul 23 | Vacirca Jeff L | Common Stock, $0.001 par value | Sale back to company | Dispose D | No | No | 0 | 295,244 | 0.00 | 0 |
31 Jul 23 | Vacirca Jeff L | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 1.13 | 75,000 | 84.75 k | 0 |
31 Jul 23 | Fischer Seth H. Z. | Common Stock, $0.001 par value | Sale back to company | Dispose D | No | No | 0 | 54,066 | 0.00 | 0 |
31 Jul 23 | Fischer Seth H. Z. | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 1.13 | 75,000 | 84.75 k | 0 |